This excerpt taken from the ABII 10-K filed Mar 31, 2008.
On April 26, 2006, we entered into a Co-Promotion and Strategic Marketing
or co-promote Abraxane® outside the U.S., other than in certain countries, should we seek to license or co-promote Abraxane®
outside of the U.S. and a right of first offer to license or co-promote nab-docetaxel in the U.S. and certain other countries should we seek to license or co-promote nab-docetaxel in those countries. STYLE="margin-top:18px;margin-bottom:0px">5. Accrued Liabilities
Accrued liabilities consisted
Additionally, legal-related expense of $23.8 million is accounted for in selling, general and